Preferences for Immunotherapy in Melanoma: A Systematic Review

被引:42
作者
Livingstone, Ann [1 ,2 ]
Agarwal, Anupriya [1 ]
Stockler, Martin R. [1 ,2 ,3 ]
Menzies, Alexander M. [4 ,5 ]
Howard, Kirsten [2 ]
Morton, Rachael L. [1 ,5 ]
机构
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[2] Univ Sydney, Sch Publ Hlth, Camperdown, NSW, Australia
[3] Univ Sydney, Cent Clin Sch, Camperdown, NSW, Australia
[4] Royal North Shore & Mater Hosp, Med Oncol, Sydney, NSW, Australia
[5] Univ Sydney, Melanoma Inst Australia, Camperdown, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
STAGE-III; ADJUVANT; INTERFERON-ALPHA-2B; IPILIMUMAB;
D O I
10.1245/s10434-019-07963-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Immunotherapy improves overall survival for patients with metatstatic melanoma and improves recurrence-free survival in the adjuvant setting, but is costly and has adverse effects. Little is known about the preferences of patients and clinicians regarding immunotherapy. This study aimed to identify factors important to patients and clinicians when deciding about immunotherapy for stages 2-4 melanoma. Methods. This study searched the Medline, EMBASE, ECONLIT, PsychINFO, and COCHRANE Systematic Reviews databases from inception to June 2018 for immunotherapy choice and preference studies. Findings were tabulated and summarized, and study reporting was assessed against recommended checklists. Results. This investigation identified eight studies assessing preferences for melanoma treatment; four studies regarding nivolumab, pembrolizumab, or ipilimumab; and four studies regarding interferon conducted in the United States, Germany, and Australia. The following 10 factors were important to decision-making: overall survival, recurrence-free survival, treatment side effects, dosing regimen, patient or payer cost, patient age, clinician or family/friend treatment recommendation, quality of life, and psychosocial effects. Overall survival was the most important factor for all respondents. The patients judged severe toxicities to be tolerable for small survival gains. The description of information about treatment harms and benefits was limited in most studies. Conclusions. Overall survival was of primary importance to patients and clinicians considering immunotherapy. Impaired quality of life due to adverse effects appeared to be a second-order consideration. Future research is required to determine preferences for contemporary combination therapies, extended treatment durations, and avoidance of chronic side effects.
引用
收藏
页码:571 / 584
页数:14
相关论文
共 25 条
[1]  
[Anonymous], 2019, Institute for Human Data Science
[2]  
Beusterien K., 2017, J CANC THER, V8, P37, DOI [10.4236/jct.2017.81004, DOI 10.4236/JCT.2017.81004]
[3]   Interferon alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon alfa-2b treatment [J].
Bramlette, Tracy B. ;
Lawson, David H. ;
Washington, Carl V. ;
Veledar, Emir ;
Johns, Barry R. ;
Brisman, Stacey F. ;
Abramova, Liana ;
Chen, Suephy C. .
DERMATOLOGIC SURGERY, 2007, 33 (01) :11-16
[4]   Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force [J].
Bridges, John F. P. ;
Hauber, A. Brett ;
Marshall, Deborah ;
Lloyd, Andrew ;
Prosser, Lisa A. ;
Regier, Dean A. ;
Johnson, F. Reed ;
Mauskopf, Josephine .
VALUE IN HEALTH, 2011, 14 (04) :403-413
[5]  
Cancer Council Australia Melanoma Guidelines Working Party. Sydney: Cancer Council Australia, 2008, CLIN PRACT GUID WORK
[6]   Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].
Eggermont, Alexander M. M. ;
Blank, Christian U. ;
Mandala, Mario ;
Long, Georgina, V ;
Atkinson, Victoria ;
Dalle, Stephane ;
Haydon, Andrew ;
Lichinitser, Mikhail ;
Khattak, Adnan ;
Carlino, Matteo S. ;
Sandhu, Shahneen ;
Larkin, James ;
Puig, Susana ;
Ascierto, Paolo A. ;
Rutkowski, Piotr ;
Schadendorf, Dirk ;
Koornstra, Rutger ;
Hernandez-Aya, Leonel ;
Maio, Michele ;
van den Eertwegh, Alfonsus J. M. ;
Grob, Jean-Jacques ;
Gutzmer, Ralf ;
Jamal, Rahima ;
Lorigan, Paul ;
Ibrahim, Nageatte ;
Marreaud, Sandrine ;
van Akkooi, Alexander C. J. ;
Suciu, Stefan ;
Robert, Caroline .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801
[7]   Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J].
Eggermont, Alexander M. M. ;
Chiarion-Sileni, Vanna ;
Grob, Jean-Jacques ;
Dummer, Reinhard ;
Wolchok, Jedd D. ;
Schmidt, Henrik ;
Hamid, Omid ;
Robert, Caroline ;
Ascierto, Paolo A. ;
Richards, Jon M. ;
Lebbe, Celeste ;
Ferraresi, Virginia ;
Smylie, Michael ;
Weber, Jeffrey S. ;
Maio, Michele ;
Konto, Cyril ;
Hoos, Axel ;
de Pril, Veerle ;
Gurunath, Ravichandra Karra ;
de Schaetzen, Gaetan ;
Suciu, Stefan ;
Testori, Alessandro .
LANCET ONCOLOGY, 2015, 16 (05) :522-530
[8]  
Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]
[9]  
GAFNI A, 1994, HEALTH SERV RES, V29, P207
[10]   Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual [J].
Gershenwald, Jeffrey E. ;
Scolyer, Richard A. ;
Hess, Kenneth R. ;
Sondak, Vernon K. ;
Long, Georgina V. ;
Ross, Merrick I. ;
Lazar, Alexander J. ;
Faries, Mark B. ;
Kirkwood, John M. ;
McArthur, Grant A. ;
Haydu, Lauren E. ;
Eggermont, Alexander M. M. ;
Flaherty, Keith T. ;
Balch, Charles M. ;
Thompson, John F. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :472-492